Naloxone controlled release - Algobate

Drug Profile

Naloxone controlled release - Algobate

Alternative Names: Naloxone extended release; Naloxone prolonged release; NLX PRT; NLX-PR

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Algobate AG; Develco Pharma Schweiz
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Phase III Constipation

Most Recent Events

  • 01 Jun 2017 Phase-III clinical trials in Constipation in Serbia (PO) (EudraCT2017-000657-39)
  • 01 Jun 2017 Algobate initiates enrolment in the phase III NAXOS trial in Constipation in Slovakia (PO) (EudraCT2017-000657-39)
  • 07 Mar 2016 Naloxone controlled release - Algobate is available for licensing in USA as of 07 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top